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Abstract
Background: Chemotherapy-induced amenorrhea (CIA) is common in young breast cancer patients. The incidence of CIA
associated with regimens involving epirubicin and taxane was not well known. Furthermore, previous studies suggested
leucopenia and amenorrhea may reflect inter-individual variations in pharmacokinetics. The purpose of this study was to
investigate the association between leucopenia after first cycle of chemotherapy and CIA in young breast cancer patients
receiving epirubicin and taxane based chemotherapy. Furthermore, the incidence of CIA was also assessed.
Methodology and Principal Findings: Between October 2008 and March 2010, 186 consecutive premenopausal patients,
treated with epirubicin and taxane based chemotherapy, were recruited. Information about CIA was collected by telephone
and out-patient clinic. Of these 186 patients, data from 165 patients were included and analyzed. Of all 165 patients, CIA
occurred in 72 patients (43.64%). In multivariate analysis, age older than 40 y (OR: 16.10, 95% CI: 6.34–40.88, P,0.001) and
previous childbearing (OR: 3.17, 95% CI: 1.06–9.47, P=0.038) were significantly associated with probability of CIA. Compared
to patients treated without taxane, patients treated with taxane-contained regimens did not have a significantly higher rate
of CIA (P.0.05). The rate of CIA in leucopenia group (52.56%) was significantly higher than that in normal leukocyte group
(34.62%) (P=0.024). In patients treated with a FEC regimen (cyclophosphamide, epirubicin and 5-fluorouracil), the rate of
CIA in leucopenia group (59.57%) was significantly higher than that in normal leukocyte group (36.84%) (P=0.037).
Conclusions: Age at diagnosis and previous childbearing were both found to significantly increase the risk of CIA, whereas
additional taxane was not associated with increased rate of CIA. Importantly, leucopenia after first cycle of chemotherapy
was associated with increased risk of CIA, which suggested that leucopenia may be an early predictor of chemotherapy-
induced infertility.
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Introduction
Breast cancer is a worldwide malignant disease. Adjuvant
chemotherapy can significantly improve disease-free survival
(DFS) and overall survival (OS) for early breast cancer patients
[1]. However, adjuvant chemotherapy can cause many long-term
side effects, such as chemotherapy-induced amenorrhea (CIA) [2–
4]. CIA is associated with menopause symptoms, infertility, and
prolonged exposure to menopausal risks such as osteoporosis [5].
More and more young patients are concerned about preserving
their fertility. Therefore, it is important to identify individuals who
are with high risk of amenorrhea after chemotherapy.
Many factors, including patients’ age, dosage of chemotherapy,
and schedule of chemotherapy are associated with the risk of CIA.
Usually, old patients had a high risk of CIA due to a reduced
number of active ovarian follicles present with increasing age [6].
Chemotherapy regimens used for the treatment of breast cancer
include cyclophosphamide, epirubicin, fluorouracil, docetaxel, and
paclitaxel. Cyclophosphamide has repeatedly been demonstrated
to be quite toxic to the ovaries [7,8]. Most regimens contain more
than one drug. The incidence of CIA associated with regimens
involving cyclophosphamide or anthracyclines ranges from 53–
89% [9]. Previous studies showed discordant results in the
incidences of taxane-induced amenorrhea. Some studies showed
that adding taxane to doxorubicin increased the risk of amenor-
rhea [10–13]. However, adding taxane to epirubicin did not
increase the risk of amenorrhea in other studies [14,15].
Epirubicin was widely used in adjuvant chemotherapy for early
breast cancer patients [16–18]. The CIA rate with epirubicin and
taxane based chemotherapy is not well known.
When the above factors were adjusted, CIA rates may be still
different in different individuals. Inter-individual variations in
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37249pharmacokinetics, influence the degree of the toxicity, may be
inner factors. Leucopenia, chemotherapy-induced bone marrow
toxicity, is common after chemotherapy, and it may be positively
related to the prognosis [19–23]. Furthermore, CIA was associated
with improved survival [24]. These studies suggested that both
leucopenia and amenorrhea may reflect inter-individual variations
in pharmacokinetics and may be markers of high bio-availability.
Rosendahl and colleagues [23] reported lower leukocyte nadir in
response to FEC regimen (cyclophosphamide, epirubicin and 5-
fluorouracil) were associated with increased risk of amenorrhea in
younger patients. Leucopenia may be an early predictor for CIA.
However, the association between leucopenia after first cycle of
chemotherapy and taxane-contained regimens induced amenor-
rhea is far less known.
In this study, we aimed to investigate the association between
leucopenia after first cycle of chemotherapy and CIA in young
breast cancer patients receiving epirubicin and taxane based
chemotherapy. A secondary aim was to evaluate the impact of
epirubicin and taxane based regimens on the rate of CIA in
Chinese patients. Furthermore, other potential risk factors of CIA
were also assessed.
Materials and Methods
Patients
The study was conducted according to ethical considerations for
observational retrospective studies, and this study was in compli-
ance with the Helsinki Declaration. All breast cancer patients
provided written informed consent for their clinical data to be
reviewed by us. Between October 2008 and March 2010, 186
consecutive premenopausal patients, treated with epirubicin and
taxane based chemotherapy, were recruited at our hospital.
Patient data were included in this retrospective study when they
met the following criteria: (1) not receiving bilateral oophorectomy
or luteinizing hormone releasing hormone (LHRH) agonists; (2)
not receiving chemotherapy previously and (3) without recurrent
disease in 12 months. Information about CIA was collected by
telephone and out-patient clinic. The following information was
collected: (1) after which cycle of chemotherapy did the patients
experience amenorrhea; (2) when did the menstruation recover; (3)
how many times did the menstruation occur after amenorrhea.
Since 5 of the 186 patients had recurrent disease within 12
months, 11 were lost during follow-up, 5 had been treated with
LHRH, data from 165 patients were included and analyzed at last.
The median follow-up time from the initiation of chemotherapy
was 26 months (range, 18–35 months).
The chemotherapy regimens were determined based on
National Comprehensive Cancer Network (NCCN) guidelines
and included: (1) FEC (5-fluorouracil 500 mg/m
2 on day 1,
epirubicin 75 mg/m
2 on day 1, and cyclophosphamide 500 mg/
m
2 on day 1) every 3 weeks for six cycles; (2) sequential-ECT: CE
every 3 weeks for four cycles followed by T (docetaxel 75 mg/m
2
on day 1 every 3 weeks or paclitaxel 175 mg/m
2 on day 1 every 2
weeks) for four cycles; (3) FEC-T: FEC every 3 weeks for three
cycles followed by docetaxel every 3 weeks for three cycles; and (4)
concurrent-ECT (docetaxel 75 mg/m
2) on day 1 every 3 weeks for
six cycles. To reach 100% dose, patients treated with taxane were
granulocyte colony stimulating factor (G-CSF) supported. All the
patients were G-CSF supported in the case of leucopenia. White
blood cell (WBC) count and neutrophilic granulocyte count were
assessed on day 7 after chemotherapy. Tamoxifen was given as
adjuvant endocrine therapy after chemotherapy when patients
were positive for estrogen receptor (ER) and/or progesterone
receptor (PR). Radiotherapy was administered to some patients
according to NCCN guidelines. Other clinical information was
collected for this study, including age, tumor size, nodal
involvement, hormone receptor status, and pathology.
Definitions of leucopenia and CIA
Premenopausal status was defined according to NCCN
guidelines. The patients with recovery menstruation were defined
as the patients in whom regular menstruation occurred more than
three times after temporary amenorrhea [25]. CIA was defined as
the cessation of menses for at least 12 months after the end of
chemotherapy [23,26,15]. Temporary amenorrhea was defined as
the menses recovered in 12 months after the end of chemotherapy.
Leucopenia in this study was defined as WBC less than 3.0610
9/L
and/or neutrophilic granulocyte count less than 1.5610
9/L on
day 7 after first cycle of chemotherapy. Otherwise, normal
leukocyte was defined as WBC more than 3.0610
9/L and
neutrophilic granulocyte count more than 1.5610
9/L on day 7
after first cycle of chemotherapy.
Statistical analysis
In this study, percentiles, median, and range were analyzed for
each continuous variable. Differences between subgroups were
examined using the chi-square test. The candidate explanatory
variables in the multivariate analysis of CIA onset were: age at
diagnosis, chemotherapy regimen, childbearing, and use of
tamoxifen. Logistic regression was used for multivariate analysis.
P,0.05 was considered significant. All analyses were performed
using the software STATA version 11.0 (Computer Resource
Center, America).
Results
In all, 165 patients were included in this study. Of these
patients, 85 were treated with a FEC regimen, 52 with a
sequential-ECT regimen, 19 with a FEC-T regimen, and 9 with
a concurrent-ECT regimen. The patients’ characteristics are
shown in Table 1. The median age of these patients was 42 y
(range, 26–53 y). Hormone receptors were positive for 106
patients, to whom tamoxifen was given. Of these 165 patients,
136 patients were diagnosed with invasive ductal carcinomas.
Taxane-contained regimens were administrated to most patients
with lymph node involved.
Risk factors of CIA
Almost all patients had amenorrhea, most of which came up
after first three cycles of chemotherapy. Of all 165 patients, CIA
occurred in 72 patients (43.64%). Most patients with temporary
amenorrhea experienced resumption of menstruation in about 8
months after the end of chemotherapy.
The incidences of CIA according to different variables were
shown in Table 2. The rate of CIA was 64.36% (65/101) in
patients older than 40 y, while the rate was only 10.94% (7/64) in
patients 40 y and younger. For 85 patients treated with a FEC
regimen, CIA occurred in 42 patients (49.41%); the CIA rates in
patients treated with a sequential-ECT, FEC-T and concurrent-
ECT were 42.31% (22/52), 21.05% (4/19) and 44.44% (4/9),
respectively. The impact of previous childbearing on the incidence
of CIA was also analyzed. Rates of CIA were 28.57%, 40.88% and
63.16% for patients with no child, one child and more than one
child, respectively. In addition, the incidences of CIA in patients
treated with tamoxifen and without tamoxifen were 44.34% and
42.37%.
In multivariate analysis (Table 3), age older than 40 y (odds
ratio (OR): 16.10, 95% confidence interval (CI): 6.34–40.88,
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9.47, P=0.038) were significantly associated with probability of
CIA. Patients treated with tamoxifen had a trend towards higher
rate of CIA (OR: 1.21, 95% CI: 0.54–2.74, P=0.647) compared
with patients not receiving tamoxifen. Compared to patients
treated with a FEC regimen, patients treated with taxane-
contained regimens did not have a significantly higher rate of
CIA (P.0.05 for all three regimens).
The relationship between leukopenia and CIA
The patients treated with concurrent-ECT regimen were G-
CSF supported after first cycle of chemotherapy, so these patients
were excluded from the analysis of the relationship between
leucopenia and CIA. In all, 156 patients were included for this
analysis (Table 4).
Of these 156 patients, 78 (50%) experienced leucopenia after
first cycle of chemotherapy. In multivariate analysis, age at
diagnosis, chemotherapy regimen, and previous childbearing were
not associated with leucopenia after first cycle of chemotherapy
(P.0.05). The rate of CIA in leucopenia group (52.56%) was
significantly higher than that in normal leukocyte group (34.62%)
(F=5.11, P=0.024). In patients treated with a FEC regimen, the
rate of CIA in leucopenia group (59.57%) was significantly higher
than that in normal leukocyte group (36.84%) (F=4.34,
P=0.037). Patients treated with a sequential ECT regimen in
leucopenia group (50%) had a trend towards higher CIA rate
compared with patients in normal leukocyte group (36.67%), but
no significant difference was observed (P.0.05) due to small
sample size.
Because there was a trend toward more leucopenia in older
patients (P=0.055), the association between leucopenia and CIA
was also analyzed in patients older than 40 y or 40 y and younger
treated with a FEC regimen. In patients older than 40 y treated
with a FEC regimen, the rate of CIA in leucopenia group (25/32)
was significantly higher than that in normal leukocyte group (12/
23) (F=4.09, P=0.043). In patients 40 y and younger treated with
a FEC regimen, the rate of CIA in leucopenia group (3/15) was
not significantly higher than that in normal leukocyte group (2/15)
(P.0.05). However, the association between leucopenia and CIA
was not analyzed in patients older than 40 y or 40 y and younger
treated with other two regimens due to small sample size.
Discussion
Chemotherapy-induced premature menopause and infertility
influence patients’ life quality seriously. It is important to
investigate the risk factors of CIA. The CIA risk of epirubicin
and taxane based chemotherapy is not well known. Our results
demonstrated that the risk of CIA was significantly related to age
at diagnosis and previous childbearing. Furthermore, compared
with the FEC regimen, taxane based regimen did not show a
higher rate of CIA. Importantly, leucopenia after first cycle of
Table 1. Patients’ characteristics.
Characteristic N (%)
Age#40 y
Yes 64 (38.79%)
No 101 (61.21%)
Tumor size
T1 84 (50.91%)
T2 66 (40.0%)
T3 5 (3.03%)
NA 10 (6.06%)
Nodal status
Positive 67 (40.61%)
Negative 87 (52.73%)
NA 11 (6.67%)
Hormone receptor status
Positive 106 (64.24%)
Negative 59 (35.76%)
Pathology
IDC 136 (82.42%)
Other 29 (17.58%)
NA, not available; IDC, invasive ductal carcinoma.
doi:10.1371/journal.pone.0037249.t001
Table 2. The incidence of CIA in different groups.
Variable No. CIA (%)
Age at diagnosis, y
.40 y 65/101 (64.36%)
#40 y 7/64 (10.94%)
Chemotherapy regimen
FEC 42/85 (49.41%)
sequential-ECT 22/52 (42.31%)
FEC-T 4/19 (21.05%)
concurrent-ECT 4/9 (44.44%)
Previous childbearing
*
0 2/7 (28.57%)
1 56/137 (40.88%)
$2 12/19 (63.16%)
Tamoxifen use
Yes 47/106 (44.34%)
No 25/59 (42.37%)
*the information about childbearing of two patients was not available.
doi:10.1371/journal.pone.0037249.t002
Table 3. Multivariate analysis of CIA.
Variable OR 95% CI P-value of CIA
Age
(.40 y vs. #40 y)
16.10 6.34–40.88 ,0.001
Chemotherapy regimen
FEC 1.0 Reference
sequential-ECT 0.30 0.08–1.14 0.077
FEC-T 0.83 0.36–1.93 0.670
concurrent-ECT 1.29 0.23–7.20 0.770
Childbearing
($2 vs.1 vs.0)
3.17 1.06–9.47 0.038
Tamoxifen use
(yes vs. no)
1.21 0.54–2.74 0.647
OR, odds ratio; CI, confidence interval.
doi:10.1371/journal.pone.0037249.t003
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epirubicin and taxane based chemotherapy.
The definitions of CIA were different in previous studies. CIA
was defined as the absence of menses for at least three consecutive
months from the point of breast cancer diagnosis in some studies
[9,10], while some authors defined it as the cessation of menses for
12 months from the beginning of chemotherapy [27,5]. The
incidence of CIA in the extant literature may be influenced by
inconsistent definitions. Most patients receiving chemotherapy will
experience irregular menses and many women may experience a
return of menses during the first year after chemotherapy [15,23].
We defined CIA as the cessation of menses for at least 12 months
after the end of chemotherapy, which can evaluate the destruction
of the ovarian reserve accurately.
Previous studies reported discordant results in the incidences of
taxane-induced amenorrhea [5,11,10,14,15]. The incidence of
CIA in patients receiving epirubicin and taxane based regimens is
not well known. In this study, epirubicin and taxane based
regimens (sequential-ECT, concurrent-ECT, and FEC-T) did not
have a higher risk of CIA than the FEC regimens, which was
similar to previous report of TE (docetaxel and epirubicin)
regimen [15]. Furthermore, additional docetaxel to FEC did not
increase the risk of amenorrhea in PACS01 trial [14]. However,
compared to adriamycin based chemotherapy, additional taxane
increased the risk of amenorrhea in previous studies [12,11,10].
The interactions of these drugs may be responsible for the
difference. Future clinical trials are needed to confirm this
interesting finding.
This study showed that age was still the most important risk
factor of CIA, which was consistent with previous studies. In
addition, we found that previous childbearing was significant
associated with CIA, which was the same as the previous study
[28]. The highly increased human chorionic gonadotropin (HCG)
in pregnancy, with the similar effects as follicle-stimulating
hormone (FSH) [29], can increase preantrla follicles differentia-
tion. The increased growth factors in pregnancy can also induce
the maturation of primordial follicles [30]. However, it is known
that FSH is down-regulated in pregnancy. Furthermore, high
estrogen concentrations in pregnancy significantly increased vessel
endothelial area [31]. Although the long-term effects of these
hormones to the ovary were not clear, the structure of the ovary in
patients with previous childbearing may be different from that in
nulliparous patients due to great changes of hormones in
pregnancy. The changes in the ovary may contribute to the
different CIA rates between patients with previous childbearing
and nulliparous patients, but the accurate underlying mechanisms
are still not known. Previous study suggested that the drop in Anti
Mu ¨llerian Hormone (AMH) may play a role in increased
recruitment of preantral follicles [32]. Measuring the dynamic
changes in AMH before and after chemotherapy in these patients
may provide information about the mechanisms underlying
different rates of CIA. This finding was obtained from these two
retrospective studies with small sample size, so future large
randomized clinical trials are needed to confirm this interesting
result. However, previous childbearing should be considered as an
important risk factor of CIA when chemotherapy was given.
Patients treated with tamoxifen had a trend towards higher
incidence of CIA, but no significant difference was observed in this
study. AMH can be used to evaluate the pool of resting primordial
follicles in the ovaries. A previous study suggested that the levels of
AMH in patients treated with, or without, tamoxifen were not
different [23], so tamoxifen may increase the risk of amenorrhea
but not ovarian failure. Randomized controlled trials with large
sample size should be performed to determine the risk factors of
CIA.
Previous studies demonstrated that chemotherapy-induced
amenorrhea and leucopenia were both associated with improved
survival [24,19–23]. Therefore, amenorrhea and leucopenia may
be markers of high bio-availability. To our knowledge, this is the
first report of a relationship between leucopenia after first cycle of
chemotherapy and CIA in patients receiving epirubicin and
taxane based chemotherapy. Patients with high bio-availability
may have increased risk of infertility. More and more young breast
cancer patients are concerned with maintaining their fertility [33].
Because leucopenia may be an early predictor of chemotherapy-
induced infertility, methods of fertility preservation should be
considered as early as possible for patients with leucopenia.
On the other hand, several limitations were present in this
study. First, this is a retrospective study with marginally significant
differences found with regard to age and leucopenia, future studies
would be required to investigate these. Second, only Chinese
patients were included in this study. Future studies should be taken
in other populations. Third, endocrinological data were not
assessed in this study. Since oligo-amenorrhoea may be caused by
tamoxifen, multivariate analysis was used to assess the risk factors
of CIA in this study.
Our study suggested age at diagnosis and previous childbearing
were both found to significantly increase the risk of CIA.
Compared to patients treated with the FEC regimen, additional
taxane did not significantly increase the rate of CIA. Importantly,
leucopenia after first cycle of chemotherapy was associated with
increased risk of CIA. When patients want to maintain their
fertility, our results should be considered. Methods of fertility
preservation should be administrated as early as possible for
patients with leucopenia.
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